First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis (Q30891802)

27 June 2017

title

First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis (English)

1 reference

27 June 2017

0 references

1 reference

1 reference

Andrea Messori

1

1 reference

27 June 2017

Valeria Fadda

series ordinal

2

1 reference

27 June 2017

Dario Maratea

series ordinal

3

1 reference

27 June 2017

Sabrina Trippoli

series ordinal

4

1 reference

27 June 2017

publication date

14 February 2015

1 reference

27 June 2017

1 reference

27 June 2017

volume

94

1 reference

27 June 2017

issue

6

1 reference

27 June 2017

page(s)

1003-1009

1 reference

Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: a multiple-treatment meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

A Bayesian network meta-analysis for binary outcome: how to do it.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Demystifying trial networks and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Early and intermediate survival after transcatheter aortic valve implantation: systematic review and meta-analysis of 14 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

Conceptual and Technical Challenges in Network Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2310-6

10.1007/S00277-015-2310-6

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference